ARYA Sciences Acquisition Corp V
ARYE News Today: Stay Updated with the Latest ARYA Sciences Acquisition Corp V News in Real Time
Find ARYE news now at Meyka AI. Stay informed with the latest ARYA Sciences Acquisition Corp V stocks updates, including price news, market analysis, and expert insights.
X Corp Fined May 23: Musk’s Platform Admits Child Safety Breach
X Corp fined $650,000 for non-compliance with Australian child safety law after three-year court battle with eSafety Commissioner.
ATLN Stock: CFO Murphy Receives $1.38M Options Grant May 22
Atlantic International Corp. CFO Kevin Murphy granted 400,000 incentive stock options worth $1.38M. Initial ownership filing filed Feb 5, 2026.
ALV Insider Buying: Naughton Acquires 27 RSUs on May 22, 2026
Autoliv insider Colin Naughton acquired 27 restricted stock units. Meyka AI analyzes the insider buying signal for ALV stock.
BAFN CEO Rogers Tate Files Initial Ownership, May 22, 2026
BayFirst Financial CEO Rogers Alfred Tate Jr files initial ownership of 22,856 Series D Preferred shares on May 21, 2026.
Best Employers Switzerland May 22: Stryker Tops 2026 Rankings
Stryker Switzerland wins 2026 best employer award. Over 51,000 Swiss employees ranked top workplaces on culture, fairness, and belonging—not just pay.
STE Maintained at Overweight by Piper Sandler, May 2026
Piper Sandler maintains Overweight rating on STERIS (STE) as stock trades near 50-day average with strong analyst consensus.
NVIDIA Corp NVDA at $219.51 falls 1.77% as Alice & Bob secures VC funding
NVIDIA Corp. shares slipped 1.77% to $219.51 on May 22, 2026, even as excitement around artificial intelligence and quantum computing stayed strong. The decline came after quantum startup Alice & Bob secured fresh venture funding backed by NVIDIA’s investment arm, NVentures. Investors are now watching whether AI giants can keep delivering strong returns after months…
XRAY: Director Mazelsky Acquires 2,638 Phantom Shares May 22, 2026
DENTSPLY SIRONA director Jonathan Mazelsky acquired 2,638 phantom stock shares via deferred compensation award on Dec 31, 2025.
ROIV Maintained at Overweight by Piper Sandler, May 2026
Piper Sandler maintains Roivant Sciences (ROIV) at Overweight rating, citing mosliciguat Phase 2 catalysts and 2026 pipeline strength.